根据眼部病理分组的玻璃体腔内注射贝伐单抗患者的血压变化。

Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology.

机构信息

Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea.

出版信息

Eye (Lond). 2010 Aug;24(8):1320-4. doi: 10.1038/eye.2010.22. Epub 2010 Apr 9.

DOI:10.1038/eye.2010.22

PMID:20379211

Abstract

PURPOSE

We evaluated the effects of intravitreal injection of bevacizumab (Avastin; Novartis, Basel, Switzerland) on blood pressure (BP) in the context of ocular vascular pathology.

METHODS

This study retrospectively examined 135 consecutive patients treated with intravitreal injections of 1.25 mg bevacizumab for retinal vascular disease; there were 61 cases of diabetic retinopathy, 30 of retinal vein occlusion, 35 of choroidal neo-vascularization (CNV), and 9 of other retinal vascular diseases. BP was measured before injection and at 30 min, 1 day, 1 week, 3 weeks, and thereafter monthly over a 6-month period.

RESULTS

In the CNV group, 30-min post-injection systolic values were significantly higher than baseline, and systolic and diastolic values after 1 day, 1 week, and 3 weeks were significantly lower than before injection. No other pressure measurement differed significantly from baseline values in the other groups.

DISCUSSION

Intravitreal bevacizumab injection is safe in terms of its effect on BP, regardless of ocular pathology.

摘要

目的

我们评估了玻璃体内注射贝伐单抗（阿瓦斯汀；诺华制药，巴塞尔，瑞士）对眼部血管病变患者血压（BP）的影响。

方法

本研究回顾性分析了 135 例连续接受玻璃体内注射 1.25mg 贝伐单抗治疗视网膜血管疾病的患者；其中 61 例为糖尿病视网膜病变，30 例为视网膜静脉阻塞，35 例为脉络膜新生血管（CNV），9 例为其他视网膜血管疾病。在注射前、注射后 30 分钟、1 天、1 周、3 周以及此后每月测量一次血压，共 6 个月。